A valid protective immune response elicited in rhesus macaques by an inactivated vaccine is capable of defending against SARS-CoV-2 infection
Hongbo Chen; Zhongping Xie; Runxiang Long; Shengtao Fan; Heng Li; Zhanlong He; Kanwei Xu; Yun Liao; Lichun Wang; Ying Zhang; Xueqi Li; Xingq Dong; Tangwei Mou; Xiaofang Zhou; Yaoyun Yang; Lei Guo; Jianbo Yang; Huiwen Zheng; Xingli Xu; Jing Li; Yan Liang; Dandan Li; Zhimei Zhao; Chao Hong; Heng Zhao; Guorun Jiang; Yanchun Che; Fengmei Yang; Yunguang Hu; Xi Wang; Jing Pu; Kaili Ma; Chen Chen; Weiguo Duan; Dong Shen; Hongling Zhao; Ruiju Jiang; Xinqiang Deng; Yan Li; Hailian Zhu; Jian Zhou; Li Yu; Mingjue Xu; Huijuan Yang; Li Yi; Zhenxin Zhou; Jiafang Yang; Nan Duan; Huan Yang; Wangli Zhao; Wei Yang; Changgui Li; Longding Liu; Qihan Li.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-235747
With the relatively serious global epidemic outbreak of SARS-CoV-2 infection, public concerns focus on not only clinical therapeutic measures and public quarantine for this disease but also the development of vaccines. The technical design of our SARS-CoV-2 inactivated vaccine provides a viral antigen that enables the exposure of more than one structural protein based upon the antibody composition of COVID-19 patients convalescent serum. This design led to valid immunity with increasing neutralizing antibody titers and a CTL response detected post-immunization of this vaccine by two injections in rhesus macaques. Further, this elicited immunoprotection in macaques enables not only to restrain completely viral replication in tissues of immunized animals, compared to the adjuvant control and those immunized by an RBD peptide vaccine, but also to significantly alleviate inflammatory lesion in lung tissues in histo-pathologic detection, compared to the adjuvant control with developed interstitial pneumonia. The data obtained from these macaques immunized with the inactivated vaccine or RBD peptide vaccine suggest that immunity with a clinically protective effect against SARS-CoV-2 infection should include not only specific neutralizing antibodies but also specific CTL responses against at least the S and N antigens.
Texto completo
Documentos relacionados